Schepetkin IA - Search Results

1

Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models.

Francavilla F, Sarcina F, Schepetkin IA, Kirpotina LN, Contino M, Schirizzi A, De Leonardis G, Khlebnikov AI, D'Alessandro R, Quinn MT, Lacivita E, Leopoldo M. Francavilla F, et al. Among authors: schepetkin ia. Eur J Med Chem. 2023 Dec 5;261:115854. doi: 10.1016/j.ejmech.2023.115854. Epub 2023 Oct 4. Eur J Med Chem. 2023. PMID: 37839346 Free PMC article.

2

Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses.

Schepetkin I. Schepetkin I. Cancer Biother Radiopharm. 1999 Aug;14(4):291-6. doi: 10.1089/cbr.1999.14.291. Cancer Biother Radiopharm. 1999. PMID: 10850314 Review.

3

Decreased luminol-dependent chemiluminescence response of neutrophils to recombinant human tumour necrosis factor in patients with gastric cancer.

Schepetkin IA, Cherdyntseva NV, Borunov EV, Skutina IL, Naumov SA. Schepetkin IA, et al. J Cancer Res Clin Oncol. 1991;117(2):172-4. doi: 10.1007/BF01613143. J Cancer Res Clin Oncol. 1991. PMID: 1848861

4

[JUN N-TERMINAL KINASES AND THEIR PHARMACOLOGICAL MODULATION OF ISCHE-MIC AND REPERFUSION INJURY OF THE BRAIN].

Shvedova MV, Anfinogenova YD, Schepetkin IA, Atochin DN. Shvedova MV, et al. Among authors: schepetkin ia. Ross Fiziol Zh Im I M Sechenova. 2017 Mar;103(3):268-83. Ross Fiziol Zh Im I M Sechenova. 2017. PMID: 30199207 Review. Russian.

5

Different metabolic effects of ganglioside GM1 in brain synaptosomes and phagocytic cells.

Avrova NF, Zakharova IO, Tyurin VA, Tyurina YY, Gamaley IA, Schepetkin IA. Avrova NF, et al. Among authors: schepetkin ia. Neurochem Res. 2002 Aug;27(7-8):751-9. doi: 10.1023/a:1020296605444. Neurochem Res. 2002. PMID: 12374210

6

Suppression by radiosensitizer AK-2123 of early phorbol myristate acetate-stimulated chemiluminescence response of human neutrophils induced by gamma-irradiation (short communication).

Schepetkin I. Schepetkin I. Cancer Biother Radiopharm. 1998 Dec;13(6):453-6. doi: 10.1089/cbr.1998.13.453. Cancer Biother Radiopharm. 1998. PMID: 10851438

7

Lucigenin luminescence elicited by microsomes and its modulation by nitroazole compounds.

Schepetkin IA. Schepetkin IA. IUBMB Life. 1999 Nov;48(5):499-504. doi: 10.1080/713803559. IUBMB Life. 1999. PMID: 10637765 Free article.

8

Osteoclastic bone resorption: normal and pathological.

Schepetkin I. Schepetkin I. Ann N Y Acad Sci. 1997 Dec 15;832:170-93. doi: 10.1111/j.1749-6632.1997.tb46246.x. Ann N Y Acad Sci. 1997. PMID: 9704046 Review. No abstract available.

9

Modeling of the anticancer action for radical derivatives of nitroazoles: quantitative structure-activity relationship (QSAR) study.

Khlebnikov A, Schepetkin I, Kwon BS. Khlebnikov A, et al. Cancer Biother Radiopharm. 2002 Apr;17(2):193-203. doi: 10.1089/108497802753773810. Cancer Biother Radiopharm. 2002. PMID: 12030113

10

Quantitative structure-activity relationships for small non-peptide antagonists of CXCR2: indirect 3D approach using the frontal polygon method.

Khlebnikov AI, Schepetkin IA, Quinn MT. Khlebnikov AI, et al. Among authors: schepetkin ia. Bioorg Med Chem. 2006 Jan 15;14(2):352-65. doi: 10.1016/j.bmc.2005.08.026. Epub 2005 Sep 22. Bioorg Med Chem. 2006. PMID: 16182534

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters